Trials / Unknown
UnknownNCT03410004
Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study of Chidamide as a single-agent treatment for patients with relapse or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Detailed description
Chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Moreover, the aim was to study the correlation of clinical efficacy to mutation of certain genes as well.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide | Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks. |
Timeline
- Start date
- 2018-01-25
- Primary completion
- 2019-09-30
- Completion
- 2020-09-30
- First posted
- 2018-01-25
- Last updated
- 2018-01-25
Source: ClinicalTrials.gov record NCT03410004. Inclusion in this directory is not an endorsement.